CanRisk Tool-A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
07
09
2020
revised:
08
10
2020
accepted:
14
12
2020
pubmed:
19
12
2020
medline:
3
2
2022
entrez:
18
12
2020
Statut:
ppublish
Résumé
The CanRisk Tool (https://canrisk.org) is the next-generation web interface for the latest version of the BOADICEA (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm) state-of-the-art risk model and a forthcoming ovarian cancer risk model. The tool captures information on family history, rare pathogenic variants in cancer susceptibility genes, polygenic risk scores, lifestyle/hormonal/clinical features, and imaging risk factors to predict breast and ovarian cancer risks and estimate the probabilities of carrying pathogenic variants in certain genes. It was implemented using modern web frameworks, technologies, and web services to make it extensible and increase accessibility to researchers and third-party applications. The design of the graphical user interface was informed by feedback from health care professionals and a formal evaluation. This freely accessible tool was designed to be user friendly for clinicians and to boost acceptability in clinical settings. The tool incorporates a novel graphical pedigree builder to facilitate collection of the family history data required by risk calculations. The CanRisk Tool provides health care professionals and researchers with a user-friendly interface to carry out multifactorial breast and ovarian cancer risk predictions. It is the first freely accessible cancer risk prediction program to carry the CE marking. There have been over 3,100 account registrations, and 98,000 breast and ovarian cancer risk calculations have been run within the first 9 months of the CanRisk Tool launch.
Sections du résumé
BACKGROUND
The CanRisk Tool (https://canrisk.org) is the next-generation web interface for the latest version of the BOADICEA (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm) state-of-the-art risk model and a forthcoming ovarian cancer risk model.
METHODS
The tool captures information on family history, rare pathogenic variants in cancer susceptibility genes, polygenic risk scores, lifestyle/hormonal/clinical features, and imaging risk factors to predict breast and ovarian cancer risks and estimate the probabilities of carrying pathogenic variants in certain genes. It was implemented using modern web frameworks, technologies, and web services to make it extensible and increase accessibility to researchers and third-party applications. The design of the graphical user interface was informed by feedback from health care professionals and a formal evaluation.
RESULTS
This freely accessible tool was designed to be user friendly for clinicians and to boost acceptability in clinical settings. The tool incorporates a novel graphical pedigree builder to facilitate collection of the family history data required by risk calculations.
CONCLUSIONS
The CanRisk Tool provides health care professionals and researchers with a user-friendly interface to carry out multifactorial breast and ovarian cancer risk predictions. It is the first freely accessible cancer risk prediction program to carry the CE marking.
IMPACT
There have been over 3,100 account registrations, and 98,000 breast and ovarian cancer risk calculations have been run within the first 9 months of the CanRisk Tool launch.
Identifiants
pubmed: 33335023
pii: 1055-9965.EPI-20-1319
doi: 10.1158/1055-9965.EPI-20-1319
pmc: PMC7611188
mid: EMS128678
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
469-473Subventions
Organisme : Wellcome Trust
ID : 203477/Z/16/Z
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C8640/A23385
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A20861
Pays : United Kingdom
Organisme : CIHR
ID : GPH-129344
Pays : Canada
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A16563
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 203477
Pays : United Kingdom
Informations de copyright
©2020 American Association for Cancer Research.
Références
CA Cancer J Clin. 2015 Jan-Feb;65(1):30-54
pubmed: 25581023
Br J Cancer. 2014 Jan 21;110(2):535-45
pubmed: 24346285
Am J Hum Genet. 1995 Mar;56(3):745-52
pubmed: 7887430
Genet Med. 2020 Nov;22(11):1803-1811
pubmed: 32624571
Bioinformatics. 2018 Mar 15;34(6):1069-1071
pubmed: 29095980
Br J Cancer. 2002 Jan 7;86(1):76-83
pubmed: 11857015
Genet Med. 2019 Aug;21(8):1708-1718
pubmed: 30643217
PLoS One. 2020 Mar 6;15(3):e0229999
pubmed: 32142536
BMC Med Inform Decis Mak. 2012 Apr 10;12:30
pubmed: 22490389
Am J Hum Genet. 2019 Jan 3;104(1):21-34
pubmed: 30554720
J Med Genet. 2015 Jul;52(7):465-75
pubmed: 26025000
Genet Med. 2016 Dec;18(12):1190-1198
pubmed: 27464310
Breast Cancer Res. 2021 Feb 15;23(1):22
pubmed: 33588869